Latest & greatest articles for prednisone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prednisone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prednisone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prednisone

61. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. (PubMed)

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. Eosinophilic inflammation, which may be a consequence of interleukin-5 action, is a characteristic feature of some forms of asthma. However, in three previous clinical trials involving patients with asthma, blockade of this cytokine did not result in a significant improvement in outcomes. We studied the prednisone-sparing effect of mepolizumab, a monoclonal antibody against interleukin-5, in a rare subgroup of patients who (...) have sputum eosinophilia and airway symptoms despite continued treatment with prednisone. Secondary objectives were to examine its effect on the number of eosinophils in sputum and blood, symptoms, and airflow limitation.In this randomized, double-blind, parallel-group trial involving patients with persistent sputum eosinophilia and symptoms despite prednisone treatment, we assigned 9 patients to receive mepolizumab (administered in five monthly infusions of 750 mg each) and 11 patients to receive

2009 NEJM Controlled trial quality: predicted high

62. Thalidomide (Thalidomide Pharmion®) in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged GE 65 years or ineligible for high dose chemotherapy

Thalidomide (Thalidomide Pharmion®) in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged GE 65 years or ineligible for high dose chemotherapy Thalidomide (Thalidomide Pharmion®) in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged GE 65 years or ineligible for high dose chemotherapy Thalidomide (Thalidomide Pharmion®) in combination with melphalan and prednisone (...) as first line treatment of patients with untreated multiple myeloma, aged GE 65 years or ineligible for high dose chemotherapy All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Thalidomide (Thalidomide Pharmion®) in combination with melphalan and prednisone as first line treatment

2009 Health Technology Assessment (HTA) Database.

63. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer (PubMed)

Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer To assess the efficacy and toxicity of the addition of estramustine to docetaxel (D) for the treatment of metastatic hormone-refractory prostate cancer.One hundred fifty patients were randomly assigned to D alone (35 mg/m(2) on days 2 and 9, every 3 weeks) or D in combination with estramustine (D/E; 280 mg orally three times a day on days (...) 1 to 5 and 8 to 12, every 3 weeks). All patients received prednisone (10 mg/d). The primary end point was prostate-specific antigen (PSA) response rate, which was defined as a decrease in PSA > or = 50% from baseline. The study was powered to test the hypothesis that D/E would improve the PSA response rate by 25%.The PSA response rate was not statistically different between the two groups. PSA of less than 4 ng/mL occurred in 29 (41%) of 71 patients receiving D/E and in 17 (25%) of 69 patients

2008 EvidenceUpdates Controlled trial quality: uncertain

64. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. (Full text)

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone. This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible for high-dose therapy.We randomly assigned 682 patients to receive nine 6-week cycles of melphalan (at a dose of 9 mg (...) per square meter of body-surface area) and prednisone (at a dose of 60 mg per square meter) on days 1 to 4, either alone or with bortezomib (at a dose of 1.3 mg per square meter) on days 1, 4, 8, 11, 22, 25, 29, and 32 during cycles 1 to 4 and on days 1, 8, 22, and 29 during cycles 5 to 9. The primary end point was the time to disease progression.The time to progression among patients receiving bortezomib plus melphalan-prednisone (bortezomib group) was 24.0 months, as compared with 16.6 months

2008 NEJM Controlled trial quality: uncertain

65. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. (PubMed)

Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Circadian rhythms are changed in patients with rheumatoid arthritis. A new modified-release delivery system has been developed which adapts the release of the administered glucocorticoid to the circadian rhythms of endogenous cortisol and disease symptoms to improve the benefit-risk ratio of glucocorticoid (...) therapy in rheumatoid arthritis. We aimed to assess the efficacy and safety of a new modified-release prednisone tablet compared with immediate-release prednisone in patients with this disease.In a 12-week, multicentre, randomised, double-blind trial, 288 patients with active rheumatoid arthritis were randomly assigned to either a modified-release prednisone tablet (n=144) or to an immediate-release prednisone tablet (n=144). The modified-release tablet was taken at bedtime and prednisone was released

2008 Lancet Controlled trial quality: predicted high

66. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer Journals Library An error has occurred in processing the XML

2007 NIHR HTA programme

67. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. (PubMed)

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. In multiple myeloma, combination chemotherapy with melphalan plus prednisone is still regarded as the standard of care in elderly patients. We assessed whether the addition of thalidomide to this combination, or reduced-intensity stem cell transplantation, would improve (...) survival.Between May 22, 2000, and Aug 8, 2005, 447 previously untreated patients with multiple myeloma, who were aged between 65 and 75 years, were randomly assigned to receive either melphalan and prednisone (MP; n=196), melphalan and prednisone plus thalidomide (MPT; n=125), or reduced-intensity stem cell transplantation using melphalan 100 mg/m2 (MEL100; n=126). The primary endpoint was overall survival. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number

2007 Lancet Controlled trial quality: predicted high

68. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. A systematic review and economic model of the clinical (...) effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, Birtle A, Palmer S, Riemsma R. Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Collins R, Fenwick E, Trowman R, Perard R

2007 Health Technology Assessment (HTA) Database.

69. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer A systematic review and economic model of the clinical (...) effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, Birtle A, Palmer S, Riemsma R CRD summary This well-conducted review concluded that docetaxel plus prednisone appears to be the most effective treatment for men with metastatic hormone-refractory prostate cancer. The review was based partially on an indirect comparison of treatments

2007 DARE.

70. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. (PubMed)

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Since 1960, oral melphalan and prednisone (MP) has been regarded as the standard of care in elderly multiple myeloma patients. This multicentre randomised trial compared oral MP plus thalidomide (MPT) with MP alone in patients aged 60-85 years.Patients with newly diagnosed multiple myeloma were randomly assigned

2006 Lancet Controlled trial quality: predicted high

71. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma (Full text)

Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment (...) of elderly patients with diffuse large B-cell lymphoma Hornberger J C, Best J H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was compared with rituximab plus

2005 NHS Economic Evaluation Database.

72. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (Full text)

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival. We compared such treatment with docetaxel plus prednisone in men with this disease.From March 2000 through June 2002, 1006 men with metastatic hormone-refractory prostate cancer received 5 mg of prednisone twice daily and were randomly assigned (...) of men, respectively, had at least a 50 percent decrease in the serum PSA level (P<0.001 for both comparisons with mitoxantrone); 22 percent, 35 percent (P=0.01), and 31 percent (P=0.08) had predefined reductions in pain; and 13 percent, 22 percent (P=0.009), and 23 percent (P=0.005) had improvements in the quality of life. Adverse events were also more common in the groups that received docetaxel.When given with prednisone, treatment with docetaxel every three weeks led to superior survival

2004 NEJM Controlled trial quality: predicted high

73. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. (Full text)

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent prostate cancer. We compared docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone-independent prostate cancer.We randomly assigned 770 men to one of two treatments, each given in 21-day cycles: 280 mg of estramustine three times (...) daily on days 1 through 5, 60 mg of docetaxel per square meter of body-surface area on day 2, and 60 mg of dexamethasone in three divided doses before docetaxel, or 12 mg of mitoxantrone per square meter on day 1 plus 5 mg of prednisone twice daily. The primary end point was overall survival; secondary end points were progression-free survival, objective response rates, and post-treatment declines of at least 50 percent in serum prostate-specific antigen (PSA) levels.Of 674 eligible patients, 338

2004 NEJM Controlled trial quality: predicted high

74. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. (Full text)

Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. In this randomized, double-blind, placebo-controlled trial, we studied the effectiveness of prednisone in reducing the risk of relapse after outpatient exacerbations of chronic obstructive pulmonary disease (COPD).We enrolled 147 patients who were being discharged from the emergency department after an exacerbation of COPD and randomly assigned them to 10 days of treatment with 40 mg of oral (...) prednisone once daily or identical-appearing placebo. All patients received oral antibiotics for 10 days, plus inhaled bronchodilators. The primary end point was relapse, defined as an unscheduled visit to a physician's office or a return to the emergency department because of worsening dyspnea, within 30 days after randomization.The overall rate of relapse at 30 days was lower in the prednisone group than in the placebo group (27 percent vs. 43 percent, P=0.05), and the time to relapse was prolonged

2003 NEJM Controlled trial quality: predicted high

75. Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma

Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 NHS Economic Evaluation Database.

76. Summaries for patients. Prednisone for rheumatoid arthritis. (PubMed)

Summaries for patients. Prednisone for rheumatoid arthritis. 11777372 2002 01 29 2016 11 24 0003-4819 136 1 2002 Jan 01 Annals of internal medicine Ann. Intern. Med. Summaries for patients. Prednisone for rheumatoid arthritis. I-26 eng Clinical Trial Journal Article Patient Education Handout Randomized Controlled Trial United States Ann Intern Med 0372351 0003-4819 0 Anti-Inflammatory Agents 0 Glucocorticoids VB0R961HZT Prednisone AIM IM Ann Intern Med. 2002 Jan 1;136(1):1-12 11777359 (...) Administration, Oral Adult Anti-Inflammatory Agents administration & dosage adverse effects Arthritis, Rheumatoid diagnostic imaging drug therapy physiopathology Disease Progression Female Fractures, Bone etiology Glucocorticoids administration & dosage adverse effects Humans Male Middle Aged Osteoporosis chemically induced complications Prednisone administration & dosage adverse effects Radiography 2002 1 5 10 0 2002 1 30 10 1 2002 1 5 10 0 ppublish 11777372 200201010-00002

2002 Annals of Internal Medicine Controlled trial quality: uncertain

77. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. (PubMed)

Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Treatment of adults with autoimmune thrombocytopenic purpura (AITP) is based more on individual experience than on results of controlled studies. We compared intravenous immunoglobulin with high-dose methylprednisolone in untreated adults with severe AITP and assessed efficacy of subsequent oral (...) steroids compared with placebo. Primary outcome was number of days with platelet count greater than 50 x 10(9)/L within the first 21 days.We did a randomised multicentre trial based on a 232 design. 122 adults with severe AITP (platelet count < or =20 x 10(9)/L) were randomly assigned to receive either intravenous immunoglobulin or high-dose methylprednisolone on days 1-3 (randomisation A), and then to receive either oral prednisone or placebo (randomisation B) on days 4-21. Analysis was by intention

2002 Lancet Controlled trial quality: predicted high

78. Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma

Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2001 PedsCCM Evidence-Based Journal Club

79. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma

Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years (...) relative to other cost-utility ratios of other health care interventions. Source of funding Supported by research grants from the Norwegian Cancer Society. Bibliographic details Gulbrandsen N, Wisloff F, Nord E, Lenhoff S, Hjorth M, Westin J. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. European Journal of Haematology 2001; 66(5): 328-336 PubMedID Other publications of related

2001 NHS Economic Evaluation Database.

80. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma.

A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2000 PedsCCM Evidence-Based Journal Club